In this study, USP32 knockdown inhibited cell growth and metastasis in vitro, and suppressed tumor growth in vivo, which suggests that USP32 acts as an oncogene in GBM and may serve as a potential target for GBM treatment. This evidence concerns the gene USP32 and glioblastoma.